Back to Search Start Over

Newly Diagnosed Metastatic Prostate Cancer: Has the Paradigm Changed?

Authors :
David F. Jarrard
Christos Kyriakopoulos
Shivashankar Damodaran
Source :
Urologic Clinics of North America. 44:611-621
Publication Year :
2017
Publisher :
Elsevier BV, 2017.

Abstract

Androgen deprivation therapy (ADT) has been conventional treatment of newly diagnosed metastatic prostate cancer for more than 70 years. However, all patients eventually become castration-resistant and a significant proportion of life span is spent in the castration-resistant state. Prospective randomized control trials have incorporated early chemotherapy along with ADT based on the hypothesis that a significant level of resistance to ADT already exists in newly diagnosed metastatic prostate cancer and ADT exhibits synergistic antitumor activity with taxanes. In this chapter we discuss the changing landscape of management of newly diagnosed metastatic prostate cancer patients based on recently published landmark randomized trials.

Details

ISSN :
00940143
Volume :
44
Database :
OpenAIRE
Journal :
Urologic Clinics of North America
Accession number :
edsair.doi.dedup.....8146f185874eff9cc9dafef2b10a4ab3